Neurocrine Biosciences, Inc’s filing revealed that its Chief Human Resources Officer Cooke Julie unloaded Company’s shares for reported $0.18 million on Feb 13 ’25. In the deal valued at $116.78 per share,1,551 shares were sold. As a result of this transaction, Cooke Julie now holds 19,544 shares worth roughly $1.98 million.
Then, GORMAN KEVIN CHARLES sold 5,844 shares, generating $681,914 in total proceeds. Upon selling the shares at $116.69, the Director now owns 521,618 shares.
Before that, SHERWIN STEPHEN A sold 13,831 shares. Neurocrine Biosciences, Inc shares valued at $1,613,923 were divested by the Director at a price of $116.69 per share. As a result of the transaction, SHERWIN STEPHEN A now holds 10,673 shares, worth roughly $1.08 million.
Needham upgraded its Neurocrine Biosciences, Inc [NBIX] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in mid April from “a Sector perform” to “an Outperform”. Deutsche Bank began covering NBIX with “Hold” recommendation on February 11, 2025.
Price Performance Review of NBIX
On Thursday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock jump 1.28% to $101.38. Over the last five days, the stock has gained 11.75%. Neurocrine Biosciences, Inc shares have fallen nearly -25.73% since the year began. Nevertheless, the stocks have fallen -23.77% over the past one year. While a 52-week high of $157.98 was reached on 01/30/25, a 52-week low of $84.23 was recorded on 04/09/25. SMA at 50 days reached $110.55, while 200 days put it at $127.07.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 99.80, which if violated will result in even more drops to 98.23. On the upside, there is a resistance level at 102.50. A further resistance level may holdings at 103.63. The Relative Strength Index (RSI) on the 14-day chart is 46.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.03, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 39.55%. Stochastics %K at 50.27% indicates the stock is a holding.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-03-31, growing by 0.56 million shares to a total of 3.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 3.23 million shares. There was a rise of 14.8%, which implies that there is a positive sentiment for the stock.
